Azitra (AZTR) Q3 2024 earnings summary

Executive summary

• Focused on developing engineered proteins and live biotherapeutic products for precision dermatology, leveraging a proprietary microbial library and AI-driven screening platform.

• Lead candidates ATR-12 and ATR-04 advanced in clinical development, with ATR-12 dosing initiated in Phase 1b and ATR-04 receiving FDA Fast Track designation and IND clearance.

• Strategic partnerships with Bayer and academic institutions support pipeline and technology development.

• Completed a $10 million follow-on offering to support ongoing operations and pipeline advancement.

• Strengthened intellectual property portfolio with new patents granted and allowed.

Financial highlights

• Total revenue for Q3 2024 was $0, down from $310,700 in Q3 2023, due to reduced reimbursable development costs from Bayer.

• Net loss for Q3 2024 was $1.0 million, a 48% improvement from $1.9 million in Q3 2023.

• Cash and cash equivalents at September 30, 2024 were $7.3 million.

• R&D expenses for Q3 2024 increased 85% year-over-year to $1.0 million.

• G&A expenses rose slightly to $1.9 million from $1.8 million year-over-year.

Outlook and guidance

• Management expects research and development expenses to increase significantly due to planned clinical trial activity.

• Initial safety data from Netherton syndrome Phase 1b trial expected in Q1 2025.

• First patient dosing for ATR-04 Phase 1/2 trial anticipated in Q1 2025.

• Topline data from ATR-12 Phase 1b trial expected by year-end 2025.

• Current cash on hand may not be sufficient to fund operations for the next twelve months; additional financing will be sought.